A study to see if HIV-1 positive subjects currently taking an anti-retroviral (ARV) regimen consisting of Truvada®, can safely switch to F/TAF without increasing the amount of HIV-1 in their blood

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-005138-39

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the efficacy of switching FTC/TDF to F/TAF versus maintaining FTC/TDF in HIV-1 positive subjects who are virologically suppressed on regimens containing FTC/TDF as determined by the proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48.


Critère d'inclusion

  • Human Immunodeficiency Virus (HIV-1) Infection